BMC Cancer最新文献

{"title":"Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.","authors":"Lin Gui, Zucheng Xie, Yan Qin, Peng Liu, Jianliang Yang, Xinrui Chen, Zhenyu Li, Ran Tao, Yuankai Shi","doi":"10.1186/s12885-025-14370-y","DOIUrl":"https://doi.org/10.1186/s12885-025-14370-y","url":null,"abstract":"<p><strong>Objective: </strong>Abexinostat, an novel pan-histone deacetylase inhibitor, induces tumor apoptosis and demonstrates therapeutic potential in B cell non-Hodgkin lymphoma (NHL). This phase 1 study investigate the safety, pharmacokinetics (PK), and efficacy of abexinostat in Chinese patients with relapsed/refractory (r/r) B cell NHL.</p><p><strong>Methods: </strong>Patients with r/r B cell NHL received abexinostat orally at escalating doses of 40 mg twice daily (bis in die, BID), 60 mg BID, and 80 mg BID with a 4-h interval, for seven days followed by a 7-day drug-free interval. Patients took abexinostat once on 3 days before day 1 (D-3) of the first cycle in single dose period. If no dose limiting toxicity (DLT) occurred from D-3 to C1D1, the continuous dose period was started from C1D1, abexinostat was given BID. The Primary endpoints were safety and PK.</p><p><strong>Results: </strong>From April 13, 2020 to November 30, 2023, 12 r/r B cell NHL patients were enrolled, including 6 follicular lymphoma (FL), 5 diffuse large B cell lymphoma (DLBCL) and 1 mantle cell lymphoma (MCL). 11 patients received at least one dose abexinostat included in the safety set. No DLT were observed, 80 mg BID was the recommended phase 2 dose (RP2D). Most treatment emergent adverse events (TEAEs) were grade 1 or 2, and grade 3 TEAEs included thrombocytopenia (2/11, 18.2%) and hypertriglyceridemia (3/11, 27.3%). The median time to maximum concentration (T_max) was 0.5-1.0 h and the median terminal elimination half-life (T_1/2) was 2.56-8.31 h. Ten patients were included in full analysis set. The objective response rate (ORR) was 40.0% (4/10, 95% CI: 12.2-73.8), including 1 complete response and 3 partial response. The ORR was 50.0% (3/6, 95% CI: 11.8-88.2) of FL patients. The median progression-free survival and duration of response of FL were 8.38 months (95% CI: 1.05-NE) and 7.82 months(95% CI: 7.33-NE), respectively. The OS was not reached.</p><p><strong>Conclusions: </strong>Abexinostat showed favorable tolerability with no DLT in Chinese patients with r/r B cell NHL. The RP2D was 80 mg BID. The plasma concentration was dose-proportional manner. The PK result demonstrated that BID \"one week on, one week off\" administration is reasonable. Promising anti-tumor activity were seen in these patients population. This result support further investigation.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov (NCT04024696). Date of registration: 18 July 2019.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"967"},"PeriodicalIF":3.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyogenic liver abscess following biliary stent placement in pancreatic cancer patients: a retrospective case series.","authors":"Dongxue Geng, Nan Lv, Yi Miao","doi":"10.1186/s12885-025-14377-5","DOIUrl":"https://doi.org/10.1186/s12885-025-14377-5","url":null,"abstract":"<p><p>Biliary stent placement is widely used in clinical, especially in patients with pancreatic cancer complicated with obstructive jaundice. Pyogenic liver abscess (PLA) is a severe complication following biliary stent placement which predominantly occurs in the right lobe of the liver, with an incidence rate ranging from 4.3% to 13.5% and a mortality rate up to 30%. It is related to the following mechanisms: retrograde bacterial infection; bile stasis and increased bile duct pH; stent-related bile duct injury; biofilm formation; immune system suppression. The main causative pathogens are gram-negative bacilli, particularly Escherichia coli and Klebsiella pneumoniae. The combination of antibiotic therapy and percutaneous transhepatic abscess drainage is the main treatment option.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"965"},"PeriodicalIF":3.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study.","authors":"Stéphane Renaud, Paul Casabianca, Pauline Diez-Andreu, Mélanie Chartier, Anne-Françoise Gaudin, Françoise Bugnard, Stève Bénard, François-Emery Cotté, Christos Chouaid","doi":"10.1186/s12885-025-14334-2","DOIUrl":"https://doi.org/10.1186/s12885-025-14334-2","url":null,"abstract":"<p><strong>Introduction: </strong>Surgery is the standard of care for eligible patients with localized or stage IIIA locally advanced non-small cell lung cancer (NSCLC) current guidelines recommend the most conservative surgeries possible. The aim of this study was to bring new real-world data on resected NSCLC epidemiology, management, and survival outcomes in patients with resected non-metastatic NSCLC.</p><p><strong>Materials and methods: </strong>This is a descriptive, non-interventional, national, retrospective claims study using data from the French National Hospitalization Database (PMSI) describing the management of patients with non-metastatic NSCLC who underwent a first lung resection (LR) between 2015 and 2019. Patients with LR performed in 2015 were followed from LR until the last registered hospital care or in-hospital death. Five-year disease-free survival (DFS [i.e., time from LR to first recurrence or death]) and overall survival (OS) were assessed.</p><p><strong>Results: </strong>The rate of patients with non-metastatic NSCLC and a first LR between 2015 and 2019 increased by an average of 4.5% per year (8,688 in 2015 vs. 10,330 in 2019). Lobectomy (79.8% vs. 84.9%) and video-assisted thoracoscopic surgery (29.6% vs. 46.4%) became more frequent. Five-year DFS was 33.7% [95%CI 29.8-37.6%] following infralobar resection, 52.3% [51.0-53.5%] after lobectomy, 42.3% [36.9-47.5%] after bilobectomy, and 33.6% [30.0-37.2%] after pneumonectomy. Respective five-year OS from LR were 58.4% [54.1-62.4], 70.2% [69.0-71.3], 59.3% [53.7-64.4], and 46.3% [42.3-50.2].</p><p><strong>Conclusions: </strong>This study highlights the increasing trend toward conservative and less invasive surgeries in resected NSCLC. Type of LR can be used as an indirect marker of disease expansion, with poorer survival outcomes in case of extensive surgeries.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"966"},"PeriodicalIF":3.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition.","authors":"Yanan Jiang, Donghui Xing, Xiang He, Wenqi Wu, Hong Xu, Huimeng Sun, Yixin Zhai, Kaiping Luo, Zhigang Zhao","doi":"10.1186/s12885-025-14257-y","DOIUrl":"https://doi.org/10.1186/s12885-025-14257-y","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematopoietic malignancy, necessitating the exploration of innovative therapeutic approaches. Targeting epigenetic mechanisms has emerged as a promising avenue for cancer treatment. EP300 belongs to the KAT3 family of histone/non-histone lysine acetyltransferases, regulating gene expression by acetylating H3K27. However, the role of EP300 and its potential as a targeted therapy in DLBCL remains unknown.</p><p><strong>Methods: </strong>Public datasets were collected to evaluate the expression and clinical significance of epigenetic modification-related genes in patients with DLBCL. Flow cytometry, colony formation, and western blotting were conducted to investigate the function of EP300. CCK8, proliferation, cell cycle, and apoptosis assays, as well as experiments in tumor-bearing mouse models were conducted to determine the therapeutic effect of the EP300 inhibitor A485 alone or in combination with the XPO1 inhibitor KPT8602. RNA-seq was used to investigate the molecular mechanisms underlying the inhibition of DLBCL development by A485.</p><p><strong>Results: </strong>EP300 is frequently overexpressed in DLBCL and is associated with poor prognosis, highlighting its potential role in lymphoma progression. In this study, we found that A485, a novel small-molecule inhibitor targeting the conserved histone acetyltransferase (HAT) domain of EP300, significantly reduced H3K27Ac levels and demonstrated potent antitumor effects in DLBCL cells, both in vitro and in vivo. Furthermore, we showed that A485 attenuated DLBCL progression by inhibiting the MYC and E2F1 pathways. Notably, the combination of A485 with the XPO1 inhibitor KPT8602 produced synergistic anti-lymphoma in vitro and in vivo effects in DLBCL cell lines. This combination therapy resulted in enhanced tumor suppression in a DLBCL xenograft model with minimal toxicity. These findings suggested that targeting EP300, particularly in conjunction with XPO1 inhibition, could represent a promising therapeutic strategy for DLBCL treatment.</p><p><strong>Conclusions: </strong>Our study elucidated that EP300 inhibition, especially in combination with XPO1 blockade, could serve as a promising therapeutic strategy for the treatment of DLBCL.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"955"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating cancer care in Cameroon: a theory-guided inquiry on patient experiences at Mbingo Baptist Hospital.","authors":"Glenn Mbah Afungchwi, Eric Makiyighome Tum, Laurie Elit","doi":"10.1186/s12885-025-14338-y","DOIUrl":"https://doi.org/10.1186/s12885-025-14338-y","url":null,"abstract":"<p><strong>Background: </strong>Cancer remains a leading cause of morbidity and mortality globally, with rising incidence rates, especially in low- and middle-income countries (LMICs). This burden is pronounced in Sub-Saharan Africa (SSA), where Cameroon faces escalating cancer challenges, primarily due to inadequate healthcare infrastructure and limited access to early detection and treatment. The study aimed to explore the experiences of cancer patients at Mbingo Baptist Hospital in Cameroon in Cameroon, focusing on the barriers to obtaining quality diagnosis, treatment, and follow-up care, and to examine the impact of these challenges on their physical, emotional, and social well-being.</p><p><strong>Methods: </strong>This study employed a qualitative descriptive design, conducting in-depth interviews with eleven cancer patients in December 2023 and January 2024. Participants were selected using purposive sampling, and data were analyzed using thematic analysis to identify key barriers in the cancer care pathway. The biopsychosocial model guided the exploration of patients' experiences, capturing the interplay between biological, psychological, and social dimensions of their healthcare journey.</p><p><strong>Results: </strong>The analysis revealed significant delays in diagnosis, substantial financial burdens, and emotional and psychological distress among patients. Key themes identified include challenges in the diagnosis and treatment processes, the financial impact of cancer care, emotional and psychosocial repercussions, and difficulties in accessing healthcare services. Despite facing these obstacles, patients also reported instances of resilience and support within their families and communities.</p><p><strong>Conclusion: </strong>The study underscores the urgent need for systemic improvements in cancer care in Cameroon and similar contexts. Enhancing healthcare infrastructure, broadening financial protection, and fostering awareness and early detection are imperative. Additionally, integrating a holistic care approach that considers the biopsychosocial aspects of patient health is crucial for improving outcomes. Addressing these recommendations requires collaborative efforts from governmental and non-governmental organizations, healthcare providers, and the international community to tailor cancer control strategies to the unique needs of LMICs, aiming to alleviate the cancer burden and enhance patient quality of life.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"958"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.","authors":"Hongquan Xing, Cong Wu, Weichang Yang, Shanshan Cai, Xinyi Zhang, Xiaoqun Ye","doi":"10.1186/s12885-025-14363-x","DOIUrl":"https://doi.org/10.1186/s12885-025-14363-x","url":null,"abstract":"<p><strong>Background: </strong>Tracheal, bronchial, and lung (TBL) cancer presents significant health challenges for individuals aged 70 and older. However, comprehensive insights into the epidemiological patterns of and risk factors for TBL cancer in this population remain limited. This study aimed to analyze the global, regional, and national burdens and trends of TBL cancer patients aged ≥ 70 years from 1990-2021.</p><p><strong>Methods: </strong>The incidence, mortality, and disability-adjusted life years (DALYs) for TBL cancer patients aged ≥ 70 years from 1990-2021 were obtained from the 2021 Global Burden of Disease study. Global trends were stratified age, sex, and sociodemographic index (SDI). Decomposition analysis identified the primary drivers of burden changes, and a global risk attribution analysis was conducted. The Bayesian Age‒Period‒Cohort (BAPC) model forecasted trends over the next 14 years. The analyses were performed with Joinpoint software and the R software.</p><p><strong>Results: </strong>From 1990-2021, the ASIRs, ASMRs, and ASDRs of TBL cancer among patients ≥ 70 years increase significantly, mainly due to aging and population growth. In the precision medicine era (2015-2021), these indicators for both sexes and males have declined, but the burden among females has increased. The burden varies across regions, with the incidence of TBL cancer increasing more severely in middle-SDI regions, East Asia, and western sub-Saharan Africa, whereas high-SDI regions have shown a decline after peaking. Although the DALY proportion of smoking decreased, it was still the main cause of TBL cancer. However, the burden of environmental particulate pollution has increased. The BAPC model predicted that in the future, the ASIR, ASMR, and ASDR for males and both sexes would decrease, whereas these indicators would either remain stable or increase among females.</p><p><strong>Conclusions: </strong>The burden of TBL cancer is increasing significantly among patients aged ≥ 70 years. Despite new hopes and approaches from precision medicine, environmental and behavioral factors still critically influence the TBL cancer burden. Future strategies could enhance subgroup-specific management and promote effective control of known risk factors.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"954"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toll-like receptor 9 (TLR9) expression correlates with cell of origin and predicts clinical outcome in diffuse large B-cell lymphoma.","authors":"Sulaf Abd Own, Ioanna Xagoraris, Konstantina Stathopoulou, Björn E Wahlin, Weicheng Ren, Mehran Ghaderi, Qiang Pan-Hammarström, Birgitta Sander, Karin E Smedby, Georgios Rassidakis","doi":"10.1186/s12885-025-14359-7","DOIUrl":"https://doi.org/10.1186/s12885-025-14359-7","url":null,"abstract":"<p><strong>Background: </strong>Biological insights beyond the cell-of-origin (COO) classification can support clinical management in diffuse large B-cell lymphoma (DLBCL). We investigated if Toll-like receptor 9 (TLR9) expression could serve as a prognostic marker in DLBCL.</p><p><strong>Method: </strong>TLR9 gene expression was analysed in four publicly available cohorts (n = 2474), and protein expression was investigated in germinal centre B-cell (GCB) and activated B-cell (ABC) DLBCL cell lines. Next, TLR9 protein expression was analysed in 120 diagnostic samples from R-CHOP-treated patients with relapsed/refractory disease (poor outcome, n = 50) or in complete remission (good outcome, n = 70). Associations were evaluated using logistic regression, estimating odds ratios (OR) and 95% confidence intervals (CI).</p><p><strong>Results: </strong>TLR9 gene expression was higher in ABC DLBCL compared to GCB DLBCL in external cohorts, and similar results were obtained for protein expression in cell lines. In patient samples, high TLR9 protein expression correlated with non-GCB type (p = 0.003) and poor outcome (p = 0.0016). High TLR9 expression remained associated with poor outcome in multivariable analysis after adjusting for COO and other clinical features (OR = 3.36, 95% CI 1.41-8.04). In exploratory analyses, a decrease of cell growth in ABC cell lines following inhibition of TLR9 activity with ODN4084-F was suggested.</p><p><strong>Conclusion: </strong>We conclude that TLR9 correlates with ABC/non-GCB phenotype and is a potential predictor of poor prognosis in DLBCL.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"959"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma.","authors":"Hao Meng, Ren-Quan Ding, Lei Jia, Xiang-Peng Chen, Yu-Hang Hu, Shu-Min Wang, Si-Qi Lv, Fan Feng","doi":"10.1186/s12885-025-14386-4","DOIUrl":"https://doi.org/10.1186/s12885-025-14386-4","url":null,"abstract":"<p><p>Porphyrins, as drug-food homologous bioactive substances, hold significant potential in nanomedicine research and photodynamic therapy (PDT). In this study, we synthesized two novel porphyrin compounds, PTA and PTBA, based on the porphyrin compound TCPP. Using these compounds, we prepared metal-porphyrin nanoparticles and evaluated their properties. Results from multiple assays demonstrated that both PTA and PTBA exhibited significantly enhanced photodynamic therapeutic activation under laser irradiation compared to TCPP. This included improved reactive oxygen species (ROS) and singlet oxygen release, as well as superior antitumor activity. When prepared as metal-porphyrin nanoparticles, all three compounds-PCN224 (TCPP with Zr⁴⁺), PMOF01 (PTA with Zr⁴⁺), and PMOF02 (PTBA with Zr⁴⁺)-showed significantly upregulated photodynamic therapeutic effects. These nanoparticles induced the accumulation of ROS and singlet oxygen in lung squamous cell carcinoma (LSCC) cells and demonstrated both in vitro and in vivo antitumor activity under laser irradiation. Notably, PMOF01 and PMOF02 exhibited much stronger antitumor effects compared to PCN224 in LSCC cells. Our findings highlight the photodynamic therapeutic potential of these novel porphyrin compounds and their nanoparticles. These results not only expand our understanding of porphyrins' antitumor capabilities but also provide new options for PDT applications.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"960"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in patients with metastatic colorectal cancer receiving cytotoxic and cytotoxic plus targeted therapy.","authors":"Hong Tham Pham, Tuan Anh Nguyen, Thao Le Ba, Vo Ngoc Minh Tran, Ronald L Castelino, Kim-Huong Truong-Nguyen, Bao Khanh Nguyen, Megan K Fischer, Viet Dung Tran, Minh-Hoang Tran","doi":"10.1186/s12885-025-14388-2","DOIUrl":"https://doi.org/10.1186/s12885-025-14388-2","url":null,"abstract":"<p><strong>Background: </strong>Targeted therapies in the treatment of metastatic colorectal cancer (mCRC) have reportedly been associated with better quality of life (QoL). Previous studies have revealed uncontrolled sources of biases or confounders that could distort this association. Given the lack of robust evidence and causal inference, we aimed to investigate the effects of targeted therapy-added regimens versus cytotoxic therapy (CyT) on QoL and components of QoL in patients with mCRC eligible for curative-intent treatment.</p><p><strong>Methods: </strong>We conducted a prospective cohort study on adults undergoing curative-intent mCRC treatment with survival prognosis of ≥ 1 year. The exposure was either CyT alone (including CAPEOX, mFOLFOX-6, mFOLFOX-7, FOLFIRI, and FOLFOXIRI) or CyT combined with targeted therapy (Cy-TaT, including CAPEOX-TaT, mFOLFOX-6-TaT, mFOLFOX-7-TaT, FOLFIRI-TaT, and FOLFOXIRI-TaT). Available targeted therapies included bevacizumab and regorafenib. The primary outcome was overall health and QoL (H/QoL), measured at month 12 using the EORTC QLQ-C30 global health status/QoL scale (in percentage point) and the EQ-5D-3L utility score. The secondary outcomes included each component of the EORTC QLQ-C30 functional scales and symptom scales/items (in percentage point), measured at month 12. Mean difference (MD) and 95% confidence interval (95% CI) were estimated using g-estimation.</p><p><strong>Results: </strong>During 12 months of follow-up, among 1143 participants (mean age 58.1, 39.4% being female, 623 in CyT group and 520 in Cy-TaT group), overall H/QoL was higher in those receiving Cy-TaT (EORTC QLQ-C30 global health status/QoL scale: MD 16.6, 95% CI 14.8 to 18.4, p < 0.001 [largest effect in CAPEOX-TaT versus CAPEOX: MD 18.7, 95% CI 15.2 to 22.2]; EQ-5D-3L utility score: MD 0.076, 95% CI 0.060 to 0.091 [largest effect in mFOLFOX-7-TaT versus mFOLFOX-7: MD 0.123, 95% CI 0.085 to 0.161]). For the EORTC QLQ-C30 functional scales and most areas of the symptom scales/items, treatment with Cy-TaT was also associated with better outcomes than with CyT, except for a contradictory association in financial difficulties. Symptoms with consistently large improvements from Cy-TaT were fatigue (MD 13.8, 95% CI 11.7 to 15.9), dyspnoea (MD 10.9, 95% CI 8.8 to 12.9), and insomnia (MD 13.0, 95% CI 10.2 to 15.7).</p><p><strong>Conclusion: </strong>Compared with those on CyT alone, patients with mCRC receiving Cy-TaT showed improved overall H/QoL, functional scales, and symptom scales/items. These benefits were consistent across most subgroups of chemotherapy, with the greatest improvements in H/QoL observed in the CAPEOX-TaT and mFOLFOX-7-TaT groups.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"957"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-frequency contrast-enhanced ultrasound in discriminating benign and malignant superficial lymph nodes: a diagnostic comparison.","authors":"Shuyuan Liang, Peng Han, Xiang Fei, Lianhua Zhu, Liuqing Peng, Fang Xie, Yukun Luo","doi":"10.1186/s12885-025-14238-1","DOIUrl":"https://doi.org/10.1186/s12885-025-14238-1","url":null,"abstract":"<p><strong>Background: </strong>Lymph nodes are critical immune system components, filtering harmful substances and acting as indicators in various disease states, including cancer. Accurate differentiation between benign and malignant superficial lymph nodes is essential for diagnosis and treatment planning. However, conventional diagnostic methods often lack the required precision. High-frequency contrast-enhanced ultrasound (H-CEUS) offers improved temporal resolution and visualization of microvascular structures, potentially providing better diagnostic accuracy than standard contrast-enhanced ultrasound (CEUS).</p><p><strong>Methods: </strong>This study included 77 patients with suspected abnormalities in superficial lymph nodes. Each patient underwent H-CEUS and CEUS examinations, with diagnoses confirmed through biopsy or surgical resection. The diagnostic performance of H-CEUS and CEUS was evaluated using sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. Chi-square tests and ROC curve analysis were employed to compare the efficacy of H-CEUS and CEUS in differentiating benign from malignant lymph nodes.</p><p><strong>Results: </strong>H-CEUS demonstrated superior diagnostic performance over CEUS, with higher sensitivity (95.92% vs. 83.67%), specificity (92.86% vs. 57.14%), and accuracy (94.80% vs. 74.03%). H-CEUS enhanced microvascular morphology visualization, facilitating more accurate differentiation between benign and metastatic lymph nodes. The area under the ROC curve for H-CEUS (0.944) was significantly greater than that for CEUS (0.704), indicating improved diagnostic capability.</p><p><strong>Conclusion: </strong>H-CEUS offers enhanced accuracy in diagnosing the nature of superficial lymph nodes, potentially improving clinical decision-making for patients with suspected lymph node malignancies. These findings support the integration of H-CEUS into routine clinical practice to achieve better diagnostic outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"961"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}